SINGAPORE--March 31, 2023--Horizon Quantum Computing, a Singapore-based company building software development tools to unlock the potential of quantum computing hardware, announced today that it has raised USD 18.1 million Series A...
Anthera announces preliminary positive results from once-daily A-002 Phase 2 cardiovascular trial
News | 01. 15. 2008
Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported preliminary results of a second Phase IIb clinical trial of A-002, for the treatment of cardiovascular disease. In this second study, administration of once-daily A-002 lowered both sPLA2 and LDL-C levels confirming the positive effects of A-002 treatment seen in the twice-daily PLASMA study (Phospholipase Levels And Serological Markers of Atherosclerosis) announced in October 2007.
